For women, the test that carries real clinical weight is Mycoplasma genitalium, and the CDC recommends it specifically for recurrent cervicitis. Ureaplasma and Mycoplasma hominis are a separate matter: the CDC states that testing for them is not recommended in the standard cervicitis workup, because they are commonly present in women with no disease at all. Most women who ask us for these tests have the same history, which is a negative standard panel and symptoms that never went away. That history is worth taking seriously. It usually needs an examination, not just another test.
This article covers what each result means for a woman, what it means in pregnancy, and where fertility questions genuinely fit.
The pattern that brings most women in
It goes roughly like this. Symptoms appear, discharge or irritation or discomfort with sex or a burning that comes and goes. A clinic runs chlamydia and gonorrhea, maybe a yeast and bacterial vaginosis check, and everything is negative. Antibiotics get prescribed anyway. Things improve for a few weeks and then return.
At that point a search turns up ureaplasma, and it looks like the answer, because it is a real organism with a real test and nobody has run it.
Sometimes it is the answer. More often the answer is one of four other things: Mycoplasma genitalium, which is the organism the guidelines actually point to here; trichomonas, which is frequently missed on older testing methods; recurrent bacterial vaginosis, which behaves exactly like this and needs a different treatment strategy than a single course; or a non-infectious cause such as a dermatologic condition or hormonal change, which no panel will ever detect.
This is why we examine before we order. Running a ureaplasma test on a symptom picture that has never been looked at tends to produce a positive result that explains nothing and a course of antibiotics that helps for a month.
Mycoplasma genitalium in women
M. genitalium is sexually transmitted and is an established cause of cervicitis. It is also associated with pelvic inflammatory disease.
The CDC’s guidance is specific about who to test: “Women with recurrent cervicitis should be tested for M. genitalium, and testing should be considered among women with PID.” At an initial presentation of cervicitis, testing “can be considered” rather than being routine. For persistent cervicitis in a woman previously treated with doxycycline or azithromycin, the guideline again says testing can be considered and treatment started based on the result.
What the CDC does not recommend is screening women without symptoms. The consequences of asymptomatic M. genitalium infection in women are not established, which means a positive result in a woman with no symptoms leaves everyone with a decision the evidence does not support.
The CDC is also candid about a limit in its own guidance on PID, noting that no published data assess the benefit of testing women with PID for M. genitalium and that the importance of directing treatment at it is unknown. We would rather tell you that than pretend the science is settled.
Treatment, and why a single azithromycin dose is the wrong move
Macrolide resistance in M. genitalium is now common. The CDC puts molecular markers for macrolide resistance at 44 to 90 percent across the United States, Canada, Western Europe and Australia, and states that a single one-gram dose of azithromycin should not be used, because it selects for resistant strains in 10 to 12 percent of cases.
The recommended approach is two-stage. Where resistance testing is available and the strain is macrolide-sensitive, doxycycline for seven days followed by an extended azithromycin course. Otherwise, doxycycline 100 mg twice daily for seven days followed by moxifloxacin 400 mg once daily for seven days.
Pelvic inflammatory disease is handled differently again. The CDC states that standard PID regimens are not effective against M. genitalium, and that where it is detected, moxifloxacin 400 mg once daily for fourteen days has been effective. Initial empiric PID treatment still gets started at presentation rather than waiting on a result, because PID is time-sensitive.
If you have been treated once with a single dose and the symptoms came back, that history is clinically useful. Bring it.
What a positive ureaplasma result means for a woman
Usually less than the internet suggests.
The CDC’s cervicitis guidance states that “no specific evidence exists for a role for Ureaplasma parvum or Ureaplasma urealyticum in cervicitis” and that testing for U. parvum, U. urealyticum and Mycoplasma hominis is not recommended. The one opening it leaves is pelvic inflammatory disease, where M. hominis and U. urealyticum “might be associated with certain PID cases.”
The European STI Guidelines Editorial Board went further in a 2018 position statement in the Journal of the European Academy of Dermatology and Venereology, concluding that “we have no evidence that we are doing more good than harm detecting and subsequently treating Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum colonizations/infections,” and recommending against routine testing and treatment in both symptomatic and asymptomatic men and women. Their reasoning includes antimicrobial resistance, which is a real cost of treating findings that were never causing disease.
So a positive ureaplasma result in a woman with no symptoms is, in most cases, a finding rather than a diagnosis. In a woman with persistent symptoms, a fully negative standard panel and a negative M. genitalium result, it becomes part of a clinical conversation, and treatment may be reasonable. That is a physician’s judgment call and it should be made out loud, with you, rather than by reflex.
Pregnancy
This comes up constantly and deserves a careful answer.
Ureaplasma and Mycoplasma hominis have been studied in relation to preterm birth and chorioamnionitis, and there is published research pointing at associations. What does not exist is a guideline recommending that pregnant women be screened for these organisms or treated for a positive result. The CDC does not recommend it. Neither does the European position statement above.
The practical answer: if you are pregnant and have symptoms, be examined, and let your obstetrician direct the workup. If you are pregnant with no symptoms and someone has offered you a ureaplasma screen, ask what they intend to do with a positive result before you agree to it. Antibiotic choices in pregnancy are narrower, and doxycycline and moxifloxacin, the two drugs at the center of M. genitalium treatment, are both avoided in pregnancy. That changes the whole calculation and it is a conversation for your OB, not a walk-in decision.
Fertility
There is no established causal link between ureaplasma and infertility, and treating ureaplasma is not a recognized fertility treatment.
That said, some reproductive endocrinologists do order the genital mycoplasma profile as part of a broader workup, particularly before certain procedures. If your specialist has asked for it, that is a legitimate reason to run it, and we will collect the specimen and send the result to you and to them. What we will not do is present the test to you as a fertility intervention on our own initiative.
Getting tested in Miami
Collection for women is a vaginal or endocervical swab, or urine depending on the panel. It takes a few minutes and is done during a normal visit.
These are send-out tests, so results take longer than the rapid tests we run in the clinic lab. A physician reviews the result and calls you. Mycoplasma genitalium testing is $350 self-pay, with the genital mycoplasma profile covering Ureaplasma species and Mycoplasma hominis priced separately. If you are using insurance, the front desk checks your coverage before the specimen is sent. Our standard panel covering HIV, syphilis, herpes 1 and 2, gonorrhea, chlamydia and hepatitis B is $450 self-pay, and chlamydia and gonorrhea PCR alone is $190. More of the menu is on our self-pay pricing page, and the front desk will quote anything not listed.
If you would rather not come in, collection can be done at your home or hotel. See STD testing at your home or hotel in Miami. For the full comparison of all three organisms, read ureaplasma and mycoplasma testing in Miami.
TrufaMED is at 9445 Harding Ave in Surfside, open seven days a week. Walk in or call (305) 537-6396.
Frequently asked questions
Should women be tested for ureaplasma?
Not routinely. The CDC states that testing for Ureaplasma parvum, Ureaplasma urealyticum and Mycoplasma hominis is not recommended in the cervicitis workup, and that no specific evidence exists for a role for either Ureaplasma species in cervicitis. Testing becomes reasonable in a narrower situation: persistent symptoms with a negative standard panel and a negative Mycoplasma genitalium result. A physician should make that call, because a positive result in a woman without symptoms usually does not warrant antibiotics.
What are the symptoms of mycoplasma or ureaplasma in women?
There is no symptom pattern unique to these organisms. Mycoplasma genitalium causes cervicitis, which can present as unusual discharge, bleeding between periods or after sex, pelvic discomfort, or no symptoms at all. Many women carrying ureaplasma have no symptoms whatsoever. Because the picture overlaps with bacterial vaginosis, trichomonas, yeast and non-infectious causes, an examination is more useful than guessing from symptoms.
Can ureaplasma cause infertility in women?
There is no established causal link, and treatment of ureaplasma is not a recognized fertility treatment. Some fertility specialists include the genital mycoplasma profile in a broader workup, and if yours has requested it we will run it. What the evidence does not support is treating a positive ureaplasma result as the explanation for infertility in a woman with no symptoms.
Is ureaplasma dangerous in pregnancy?
Ureaplasma and Mycoplasma hominis have been studied in connection with preterm birth and chorioamnionitis, but no major guideline recommends screening pregnant women or treating a positive result. If you are pregnant and have symptoms, be examined and let your obstetrician direct the workup. Note that doxycycline and moxifloxacin, the two drugs central to Mycoplasma genitalium treatment, are both avoided in pregnancy, so treatment decisions in pregnancy belong with your OB.
Who should be tested for Mycoplasma genitalium?
The CDC recommends testing women with recurrent cervicitis, and says testing should be considered among women with pelvic inflammatory disease. At a first presentation of cervicitis it can be considered rather than being routine. Screening women with no symptoms is specifically not recommended, because the consequences of asymptomatic infection are not established.
My standard STD panel was negative but I still have symptoms. What now?
Get examined rather than ordering another panel first. The common explanations at that point are Mycoplasma genitalium, trichomonas missed on older testing, recurrent bacterial vaginosis, or a non-infectious cause such as a dermatologic or hormonal issue that no panel detects. Which tests to add depends on what the examination shows.
How is Mycoplasma genitalium treated in women?
With a two-stage course. Where resistance testing is available and the strain is macrolide-sensitive, doxycycline for seven days then an extended azithromycin course. Otherwise doxycycline 100 mg twice daily for seven days followed by moxifloxacin 400 mg once daily for seven days. For pelvic inflammatory disease with M. genitalium detected, the CDC notes moxifloxacin 400 mg daily for fourteen days has been effective, and that standard PID regimens are not effective against it. A single one-gram azithromycin dose is specifically advised against.
Does my partner need treatment?
For Mycoplasma genitalium, partner treatment is part of the conversation, because reinfection is a common reason symptoms return after a correct course. For a ureaplasma finding with no symptoms, treating a partner is usually not indicated. The physician will tell you which situation you are in rather than leaving you to guess.
How long do the results take?
Mycoplasma genitalium and the genital mycoplasma profile are send-out tests, so they take longer than the rapid tests run in our clinic lab. A physician reviews the result and calls you with it. Faster tests such as chlamydia and gonorrhea PCR or rapid HIV can be collected at the same visit.